TMCI vs. AORT, CDRE, ESTA, TNDM, FNA, BLFS, LQDA, SSII, PLSE, and INMD
Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), Pulse Biosciences (PLSE), and InMode (INMD). These companies are all part of the "medical equipment" industry.
Treace Medical Concepts vs. Its Competitors
Artivion (NYSE:AORT) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.
86.4% of Artivion shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 7.6% of Artivion shares are owned by insiders. Comparatively, 27.7% of Treace Medical Concepts shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Artivion has higher revenue and earnings than Treace Medical Concepts. Artivion is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.
Artivion presently has a consensus target price of $32.40, indicating a potential upside of 3.80%. Treace Medical Concepts has a consensus target price of $10.52, indicating a potential upside of 80.82%. Given Treace Medical Concepts' higher possible upside, analysts plainly believe Treace Medical Concepts is more favorable than Artivion.
In the previous week, Artivion and Artivion both had 2 articles in the media. Treace Medical Concepts' average media sentiment score of 0.96 beat Artivion's score of 0.62 indicating that Treace Medical Concepts is being referred to more favorably in the news media.
Artivion has a net margin of -5.49% compared to Treace Medical Concepts' net margin of -25.14%. Artivion's return on equity of 3.63% beat Treace Medical Concepts' return on equity.
Artivion has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Summary
Artivion beats Treace Medical Concepts on 12 of the 16 factors compared between the two stocks.
Get Treace Medical Concepts News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Treace Medical Concepts Competitors List
Related Companies and Tools
This page (NASDAQ:TMCI) was last updated on 7/15/2025 by MarketBeat.com Staff
Free TMCI Stock Alerts